## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Highlights</td>
<td>1</td>
</tr>
<tr>
<td>Introduction</td>
<td>2</td>
</tr>
<tr>
<td>Section 1: National and Regional Estimates</td>
<td>4</td>
</tr>
<tr>
<td>Section 2: Major Drug Categories</td>
<td>15</td>
</tr>
<tr>
<td>Appendix A: Statistical Methodology</td>
<td>19</td>
</tr>
<tr>
<td>Appendix B: NFLIS-Drug Participating and Reporting Forensic Laboratories</td>
<td>23</td>
</tr>
<tr>
<td>Appendix C: NFLIS-Drug Benefits and Limitations</td>
<td>24</td>
</tr>
<tr>
<td>Public Domain Notice and Obtaining Copies of This Publication</td>
<td>26</td>
</tr>
</tbody>
</table>
Highlights

■ From January 1, 2019, through June 30, 2019, an estimated 441,960 distinct drug cases were submitted to State and local laboratories in the United States and analyzed by September 30, 2019. From these cases, an estimated 800,283 drug reports were identified. Methamphetamine was the most frequently reported drug (209,439 reports), followed by cannabis/THC (165,865 reports), cocaine (108,762 reports), and heroin (68,586 reports). These four most frequently reported drugs accounted for approximately 69% of all drug reports.

■ Nationally, fentanyl reports dramatically increased from 2014 through the first half of 2019 ($p < .05$). Alprazolam reports increased significantly from 2014 to the first half of 2016, then decreased through the first half of 2019. Oxycodone reports showed a steady decline from 2011 through the first half of 2019. Buprenorphine reports increased from 2013 to the first half of 2019. Hydrocodone reports steadily decreased from the second half of 2010 through the first half of 2019. Amphetamine reports steadily increased from 2007 through the first half of 2018, then decreased in the first half of 2019.

■ Regionally, fentanyl reports in all regions increased significantly from 2014 through the first half of 2019. Alprazolam reports for all four regions decreased from the first half of 2018 to the first half of 2019. Oxycodone reports decreased from 2011 through the first half of 2019 in all regions. Buprenorphine reports in the South region showed an S-shaped trend, and along with the remaining regions showed increases in reports through the first half of 2019. Hydrocodone reports significantly increased in all regions from 2001 through at least 2009, then steadily decreased through the first half of 2019. Amphetamine reports steadily increased from the second half of 2007 through the first half of 2019 in the Northeast region and through the first half of 2018 in the Midwest and South regions, while reports in the West region remained steady.

■ Fentanyl accounted for 48% of narcotic analgesic reports. Alprazolam accounted for 49% of tranquilizer and depressant reports. Among identified synthetic cannabinoids, 5F-MDMB-PICA, 5F-ADB, and FUB-AMB accounted for 48% of the reports.

■ Methamphetamine reports showed increases in all regions beginning around 2010 and 2011 and continuing through the first half of 2019, except that the West region had a decrease in reports from the first half of 2016 to the second half of 2017, with a significant increase in the first half of 2019. Cannabis/THC reports in the Northeast region increased from the second half of 2003 to the first half of 2008 before decreasing through the first half of 2019, while the remaining regions had more rolling decreasing trend lines through 2018. From 2018 to the first half of 2019, cannabis/THC reports in the Northeast region increased, while reports in the Midwest region decreased. Cocaine reports showed slight increases in all regions beginning in the first half of 2017, with reports in the Northeast region continuing to increase through the first half of 2019. Heroin reports decreased beginning in the second half of 2015 for the West and Midwest regions and in the first half of 2016 for the Northeast and South regions, while reports in the West region increased from the second half of 2017 through the first half of 2019. Reports of acetyl fentanyl, which first appeared in NFLIS-Drug in 2013, increased in all regions in the first half of 2015, then significantly increased from 2017 through the first half of 2019 in the Northeast, South, and Midwest regions. Acetyl fentanyl reports in the West region increased from the second half of 2017 through the second half of 2018, then decreased in the first half of 2019. MDMA reports remained steady from 2012 through the first half of 2019 in the Northeast and West regions, while reports in the Midwest and South regions increased from 2017 through the first half of 2019.

■ Methamphetamine was the most frequently reported drug in the West (47%), Midwest (28%), and South (27%) regions, while cannabis/THC was the most frequently reported drug in the Northeast (25%) region.

■ Nationwide, methamphetamine reports increased from 2011 through the first half of 2019. Cannabis/THC reports decreased from the second half of 2010 through the first half of 2019. Cocaine reports significantly decreased from 2008 through 2014, then remained steady through the first half of 2019. Heroin reports increased from 2006 through 2015, then decreased through the first half of 2019. Acetyl fentanyl reports increased from 2013 through the second half of 2015, decreased through the first half of 2017, then steadily increased to the first half of 2019. MDMA reports sharply decreased from 2010 to 2013, then gradually increased through the first half of 2019.

---

2 Curved trends are sometimes described as U-shaped (e.g., decreasing in earlier years and increasing in recent years) and S-shaped (i.e., two turns in the trend, roughly either increasing-decreasing-increasing or decreasing-increasing-decreasing). See Appendix A for a more detailed methodology discussion.
Introduction

The National Forensic Laboratory Information System (NFLIS) is a program of the Drug Enforcement Administration (DEA), Diversion Control Division. NFLIS-Drug systematically collects drug identification results and associated information from drug cases submitted to and analyzed by Federal, State, and local forensic laboratories. These laboratories analyze controlled and noncontrolled substances secured in law enforcement operations across the country, making NFLIS-Drug an important resource in monitoring illicit drug use and trafficking, including the diversion of legally manufactured pharmaceuticals into illegal markets. NFLIS-Drug includes information on the specific substance and the characteristics of drug evidence, such as purity, quantity, and drug combinations. These data are used to support drug scheduling efforts and to inform drug policy and drug enforcement initiatives nationally and in local communities around the country.

NFLIS-Drug is a comprehensive information system that includes data from forensic laboratories that handle the Nation’s drug analysis cases. The NFLIS-Drug participation rate, defined as the percentage of the national drug caseload represented by laboratories that have joined NFLIS, is currently more than 98%. NFLIS-Drug includes 50 State systems and 103 local or municipal laboratories/laboratory systems, representing a total of 278 individual laboratories. The NFLIS-Drug database also includes Federal data from DEA and U.S. Customs and Border Protection (CBP) laboratories.

This publication presents the results of drug cases submitted to State and local laboratories from January 1, 2019, through June 30, 2019, that were analyzed by September 30, 2019. Data from Federal laboratories for the same period of time are also included in this publication. The data presented in this publication include all drugs mentioned in the laboratories’ reported drug items.

Section 1 of this publication provides national and regional estimates for the 25 most frequently identified drugs, as well as national and regional trends from January 2001 through June 2019. Section 2 presents estimates of specific drugs by drug category. All estimates are based on the NEAR approach (National Estimates Based on All Reports).

Appendix A provides details on the methodology used in preparing the data presented in this publication. Appendix B includes a list of NFLIS-Drug participating and reporting laboratories. The benefits and limitations of NFLIS-Drug are presented in Appendix C.
Participating Laboratories, by U.S. Census Region

Note: See Appendix B for a listing of NFLIS-Drug participating and reporting forensic laboratories.
Section 1: National and Regional Estimates

This section presents national and regional estimates of drugs submitted to State and local laboratories from January 1, 2019, through June 30, 2019, that were analyzed by September 30, 2019 (see Table 1.1). National and regional drug estimates include all drug reports mentioned in laboratories’ reported drug items. National drug case estimates are also presented (see Table 1.2). In addition, semiannual trends are presented for selected drugs from January 2001 through June 2019.

The NEAR approach (National Estimates Based on All Reports) was used to produce estimates for the Nation and for the U.S. census regions. The NEAR approach uses all NFLIS-Drug reporting laboratories. Appendix A provides a detailed description of the methods used in preparing these estimates.

### Table 1.1

**National and Regional Estimates for the 25 Most Frequently Identified Drugs**

*Estimated number and percentage of total drug reports submitted to laboratories from January 1, 2019, through June 30, 2019, and analyzed by September 30, 2019*

<table>
<thead>
<tr>
<th>Drug</th>
<th>National</th>
<th></th>
<th>West</th>
<th></th>
<th>Midwest</th>
<th></th>
<th>Northeast</th>
<th></th>
<th>South</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number</td>
<td>Percent</td>
<td>Number</td>
<td>Percent</td>
<td>Number</td>
<td>Percent</td>
<td>Number</td>
<td>Percent</td>
<td>Number</td>
<td>Percent</td>
</tr>
<tr>
<td>Methamphetamine</td>
<td>209,439</td>
<td>26.17%</td>
<td>59,874</td>
<td>47.05%</td>
<td>55,812</td>
<td>27.67%</td>
<td>6,061</td>
<td>4.17%</td>
<td>87,692</td>
<td>26.89%</td>
</tr>
<tr>
<td>Cannabis/THC</td>
<td>165,865</td>
<td>20.73%</td>
<td>17,614</td>
<td>13.84%</td>
<td>40,034</td>
<td>19.85%</td>
<td>36,073</td>
<td>24.84%</td>
<td>72,144</td>
<td>22.12%</td>
</tr>
<tr>
<td>Cocaine</td>
<td>108,762</td>
<td>13.59%</td>
<td>5,858</td>
<td>6.97%</td>
<td>24,298</td>
<td>12.05%</td>
<td>29,813</td>
<td>20.53%</td>
<td>46,062</td>
<td>14.13%</td>
</tr>
<tr>
<td>Heroin</td>
<td>68,586</td>
<td>8.57%</td>
<td>17,675</td>
<td>13.89%</td>
<td>15,547</td>
<td>7.71%</td>
<td>18,128</td>
<td>12.48%</td>
<td>17,235</td>
<td>5.29%</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>47,814</td>
<td>5.97%</td>
<td>2,750</td>
<td>2.16%</td>
<td>14,094</td>
<td>6.99%</td>
<td>19,625</td>
<td>13.51%</td>
<td>11,346</td>
<td>3.48%</td>
</tr>
<tr>
<td>Alprazolam</td>
<td>14,586</td>
<td>1.82%</td>
<td>1,809</td>
<td>1.42%</td>
<td>3,406</td>
<td>1.69%</td>
<td>1,979</td>
<td>1.36%</td>
<td>7,393</td>
<td>2.27%</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>11,433</td>
<td>1.43%</td>
<td>976</td>
<td>0.76%</td>
<td>2,474</td>
<td>1.23%</td>
<td>2,545</td>
<td>1.75%</td>
<td>5,447</td>
<td>1.67%</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>10,245</td>
<td>1.28%</td>
<td>811</td>
<td>0.63%</td>
<td>2,529</td>
<td>1.25%</td>
<td>2,462</td>
<td>1.70%</td>
<td>4,452</td>
<td>1.37%</td>
</tr>
<tr>
<td>Acetylfentanyl</td>
<td>7,307</td>
<td>0.91%</td>
<td>29</td>
<td>0.02%</td>
<td>2,420</td>
<td>1.20%</td>
<td>3,238</td>
<td>2.23%</td>
<td>1,620</td>
<td>0.50%</td>
</tr>
<tr>
<td>Hydrocodone</td>
<td>6,537</td>
<td>0.82%</td>
<td>833</td>
<td>0.65%</td>
<td>1,869</td>
<td>0.93%</td>
<td>263</td>
<td>0.18%</td>
<td>3,572</td>
<td>1.10%</td>
</tr>
<tr>
<td>Amphetamine</td>
<td>5,805</td>
<td>0.73%</td>
<td>396</td>
<td>0.31%</td>
<td>1,559</td>
<td>0.77%</td>
<td>1,000</td>
<td>0.69%</td>
<td>2,849</td>
<td>0.87%</td>
</tr>
<tr>
<td>Tramadol</td>
<td>4,645</td>
<td>0.58%</td>
<td>224</td>
<td>0.18%</td>
<td>1,616</td>
<td>0.80%</td>
<td>1,075</td>
<td>0.74%</td>
<td>1,730</td>
<td>0.53%</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>4,191</td>
<td>0.52%</td>
<td>279</td>
<td>0.22%</td>
<td>1,116</td>
<td>0.55%</td>
<td>766</td>
<td>0.53%</td>
<td>2,030</td>
<td>0.62%</td>
</tr>
<tr>
<td>MDMA</td>
<td>3,558</td>
<td>0.44%</td>
<td>942</td>
<td>0.74%</td>
<td>1,270</td>
<td>0.63%</td>
<td>307</td>
<td>0.21%</td>
<td>1,037</td>
<td>0.32%</td>
</tr>
<tr>
<td>Eutylone</td>
<td>2,800</td>
<td>0.35%</td>
<td>0</td>
<td>0.00%</td>
<td>155</td>
<td>0.08%</td>
<td>115</td>
<td>0.08%</td>
<td>2,530</td>
<td>0.78%</td>
</tr>
<tr>
<td>Naloxone</td>
<td>2,305</td>
<td>0.29%</td>
<td>107</td>
<td>0.08%</td>
<td>337</td>
<td>0.17%</td>
<td>678</td>
<td>0.47%</td>
<td>1,183</td>
<td>0.36%</td>
</tr>
<tr>
<td>Psilocin/psilocin</td>
<td>2,232</td>
<td>0.28%</td>
<td>676</td>
<td>0.53%</td>
<td>784</td>
<td>0.39%</td>
<td>194</td>
<td>0.13%</td>
<td>578</td>
<td>0.18%</td>
</tr>
<tr>
<td>5F-MDMB-PICA</td>
<td>2,227</td>
<td>0.28%</td>
<td>147</td>
<td>0.12%</td>
<td>366</td>
<td>0.18%</td>
<td>736</td>
<td>0.51%</td>
<td>978</td>
<td>0.30%</td>
</tr>
<tr>
<td>Phencyclidine (PCP)</td>
<td>2,146</td>
<td>0.27%</td>
<td>145</td>
<td>0.11%</td>
<td>490</td>
<td>0.24%</td>
<td>542</td>
<td>0.37%</td>
<td>969</td>
<td>0.30%</td>
</tr>
<tr>
<td>Lysergic acid diethylamide (LSD)</td>
<td>2,047</td>
<td>0.26%</td>
<td>361</td>
<td>0.28%</td>
<td>859</td>
<td>0.43%</td>
<td>227</td>
<td>0.16%</td>
<td>600</td>
<td>0.18%</td>
</tr>
<tr>
<td>ANPP</td>
<td>2,010</td>
<td>0.25%</td>
<td>54</td>
<td>0.04%</td>
<td>399</td>
<td>0.20%</td>
<td>932</td>
<td>0.64%</td>
<td>626</td>
<td>0.19%</td>
</tr>
<tr>
<td>Cannabidiol (CBD)</td>
<td>1,767</td>
<td>0.22%</td>
<td>87</td>
<td>0.07%</td>
<td>483</td>
<td>0.24%</td>
<td>64</td>
<td>0.04%</td>
<td>1,133</td>
<td>0.35%</td>
</tr>
<tr>
<td>5F-ADB</td>
<td>1,673</td>
<td>0.21%</td>
<td>26</td>
<td>0.02%</td>
<td>422</td>
<td>0.21%</td>
<td>223</td>
<td>0.15%</td>
<td>1,002</td>
<td>0.31%</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>1,572</td>
<td>0.20%</td>
<td>87</td>
<td>0.07%</td>
<td>351</td>
<td>0.17%</td>
<td>344</td>
<td>0.24%</td>
<td>790</td>
<td>0.24%</td>
</tr>
<tr>
<td>Morphine</td>
<td>1,529</td>
<td>0.19%</td>
<td>255</td>
<td>0.20%</td>
<td>459</td>
<td>0.23%</td>
<td>157</td>
<td>0.11%</td>
<td>658</td>
<td>0.20%</td>
</tr>
</tbody>
</table>

**Top 25 Total**

691,078 86.35% 114,728 90.16% 173,148 85.84% 127,546 87.82% 275,655 84.53%

**All Other Drug Reports**

109,205 13.65% 12,515 9.84% 28,560 14.16% 17,692 12.18% 50,439 15.47%

**Total Drug Reports**

800,283 100.00% 127,243 100.00% 201,708 100.00% 145,238 100.00% 326,095 100.00%

**Notes:**

1. Sample n’s and 95% confidence intervals for all estimates are available on request.
2. Numbers and percentages may not sum to totals because of rounding.

MDMA=3,4-methylenedioxymethamphetamine
5F-MDMB-PICA=methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate
ANPP=4-anilino-N-phenethyl-4-piperidine

SF-ADB=methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate

4 | NFLIS-DRUG 2019 MIDYEAR REPORT
### Table 1.2

**NATIONAL CASE ESTIMATES**
Top 25 estimated number of drug-specific cases and their percentage of distinct cases, January 1, 2019, through June 30, 2019

<table>
<thead>
<tr>
<th>Drug</th>
<th>Number</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methamphetamine</td>
<td>155,589</td>
<td>35.20%</td>
</tr>
<tr>
<td>Cannabis/THC</td>
<td>114,929</td>
<td>26.00%</td>
</tr>
<tr>
<td>Cocaine</td>
<td>82,807</td>
<td>18.74%</td>
</tr>
<tr>
<td>Heroin</td>
<td>51,087</td>
<td>11.56%</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>35,475</td>
<td>8.03%</td>
</tr>
<tr>
<td>Alprazolam</td>
<td>12,289</td>
<td>2.78%</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>9,124</td>
<td>2.06%</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>8,953</td>
<td>2.03%</td>
</tr>
<tr>
<td>Hydrocodone</td>
<td>5,471</td>
<td>1.24%</td>
</tr>
<tr>
<td>Acetyl fentanyl</td>
<td>5,456</td>
<td>1.23%</td>
</tr>
<tr>
<td>Amphetamine</td>
<td>4,909</td>
<td>1.11%</td>
</tr>
<tr>
<td>Tramadol</td>
<td>3,890</td>
<td>0.88%</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>3,687</td>
<td>0.83%</td>
</tr>
<tr>
<td>MDMA</td>
<td>2,670</td>
<td>0.60%</td>
</tr>
<tr>
<td>Naloxone</td>
<td>2,213</td>
<td>0.50%</td>
</tr>
<tr>
<td>ANPP</td>
<td>1,832</td>
<td>0.41%</td>
</tr>
<tr>
<td>Psilocin/psilocibin</td>
<td>1,829</td>
<td>0.41%</td>
</tr>
<tr>
<td>Phencyclidine (PCP)</td>
<td>1,820</td>
<td>0.41%</td>
</tr>
<tr>
<td>Ecstasy</td>
<td>1,768</td>
<td>0.40%</td>
</tr>
<tr>
<td>Lysergic acid diethylamide (LSD)</td>
<td>1,724</td>
<td>0.39%</td>
</tr>
<tr>
<td>5F-MDMB-PICA</td>
<td>1,615</td>
<td>0.37%</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>1,381</td>
<td>0.31%</td>
</tr>
<tr>
<td>Morphine</td>
<td>1,350</td>
<td>0.31%</td>
</tr>
<tr>
<td>SF-ADB</td>
<td>1,247</td>
<td>0.28%</td>
</tr>
<tr>
<td>Diazepam</td>
<td>1,240</td>
<td>0.28%</td>
</tr>
</tbody>
</table>

**Top 25 Total**
514,359 116.38%

**All Other Drugs**
83,332 18.86%

**Total All Drugs**
597,691 135.24%

---

#### Drugs Reported by Federal Laboratories

The majority of drug reports presented in this section are from the eight U.S. Drug Enforcement Administration (DEA) laboratories. The data reflect results of substance evidence from drug seizures, undercover drug buys, and other evidence analyzed at DEA laboratories located across the country. DEA data include results for drug cases submitted by DEA agents, other Federal law enforcement agencies, and select local police agencies. Although DEA data capture both domestic and international drug cases, the results presented in this section describe only those drugs obtained within the United States. In addition to drug reports from the DEA, reports from seven U.S. Customs and Border Protection laboratories are also included.

#### Most Frequently Reported Drugs by Federal Laboratories

Number and percentage of drug reports submitted to laboratories from January 1, 2019, through June 30, 2019, and analyzed by September 30, 2019

<table>
<thead>
<tr>
<th>Drug</th>
<th>Number</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methamphetamine</td>
<td>6,936</td>
<td>22.49%</td>
</tr>
<tr>
<td>Cocaine</td>
<td>3,963</td>
<td>12.85%</td>
</tr>
<tr>
<td>Heroin</td>
<td>3,262</td>
<td>10.58%</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>2,396</td>
<td>7.77%</td>
</tr>
<tr>
<td>Cannabis/THC</td>
<td>716</td>
<td>2.32%</td>
</tr>
<tr>
<td>Tramadol</td>
<td>411</td>
<td>1.33%</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>291</td>
<td>0.94%</td>
</tr>
<tr>
<td>Acetyl fentanyl</td>
<td>281</td>
<td>0.91%</td>
</tr>
<tr>
<td>ANPP</td>
<td>178</td>
<td>0.58%</td>
</tr>
<tr>
<td>Alprazolam</td>
<td>167</td>
<td>0.54%</td>
</tr>
</tbody>
</table>

**All Other Drug Reports**
12,233 39.67%

**Total Drug Reports**
30,834 100.00%

---

1 Federal drug reports in this table include 26,266 reports from Drug Enforcement Administration laboratories and 4,568 reports from U.S. Customs and Border Protection laboratories.

2 Numbers and percentages may not sum to totals because of rounding.
The remainder of this section presents semiannual national and regional trends of selected drugs submitted to State and local laboratories during each six-month data reference period and analyzed within three months of the end of each six-month period. The trend analyses test the data for the presence of linear and curved trends using statistical methods described in more detail in Appendix A, including the improvement to the covariance estimation in the long-term analysis introduced in 2016. Curved trends are sometimes described as U-shaped (e.g., decreasing in earlier years and increasing in recent years) and S-shaped (i.e., two turns in the trend, roughly either increasing-decreasing-increasing or decreasing-increasing-decreasing). Because the trends are determined through regression modeling, the descriptions of the trends detailed in this section may differ slightly from the plotted lines of estimates featured in Figures 1.1 through 1.16. Estimates include all drug reports identified among the NFLIS-Drug laboratories’ reported drug items. Between the first half of 2001 and the first half of 2019, the total estimated number of drug reports decreased approximately 10%, from 887,939 to 800,283.

**National prescription drug trends**

Figures 1.1 and 1.2 present national trends for the estimated number of prescription drug reports that were identified as fentanyl, alprazolam, oxycodone, buprenorphine, hydrocodone, and amphetamine. Significant ($p < .05$) results include the following:

- **Fentanyl reports** remained steady from 2001 to 2013, with one noticeable increase in reports in the second half of 2006. Fentanyl reports continued to remain steady until dramatic increases occurred from 2014 through the first half of 2019.

- **Alprazolam reports** showed an overall increase from the second half of 2003 to the first half of 2010, followed by a decrease through 2013. Alprazolam reports significantly increased from 2014 to the first half of 2016, with a reduced number of reports through the first half of 2019.

- **Oxycodone reports** showed steady increases from 2001 to 2004, followed by a decrease in 2005. Reports dramatically increased from 2006 to 2010, then showed a steady decline through the first half of 2019.

- **Buprenorphine reports** showed an S-shaped trend, with a steady increase in reports from the first half of 2006 through the first half of 2010, then another increase from 2013 to first half of 2019.

- **Hydrocodone reports** had dramatic increases from 2001 to the first half of 2010, followed by steady decreases through the first half of 2019.

- **Amphetamine reports** were steady from 2001 through 2004, followed by a decrease in 2005; amphetamine reports then steadily increased from 2007 through the first half of 2018 until a decrease in the first half of 2019.

Significance tests were also performed on differences from the first half of 2018 to the first half of 2019 to identify more recent changes. Across these two periods, reports of fentanyl (from 37,140 to 47,814 reports) and buprenorphine (from 8,921 to 10,245 reports) increased significantly ($p < .05$). Reports of alprazolam (from 19,925 to 14,586 reports), oxycodone (from 13,351 to 11,433 reports), hydrocodone (from 7,997 to 6,537 reports), and amphetamine (from 6,452 to 5,805 reports) decreased significantly.
Figure 1.1 National trend estimates for fentanyl, alprazolam, and oxycodone, January 2001–June 2019

Figure 1.2 National trend estimates for buprenorphine, hydrocodone, and amphetamine, January 2001–June 2019

Note: Estimates are shown in half-year increments for each year from January to June 2001 through January to June 2019.

1 A dashed trend line indicates that estimates did not meet the criteria for precision or reliability. See Appendix A for a more detailed methodology discussion.
Other national drug trends

Figures 1.3 and 1.4 present national trends for reports of methamphetamine, cannabis/THC, cocaine, heroin, acetyl fentanyl, and MDMA. Significant ($p < .05$) results include the following:

- Methamphetamine reports increased from 2001 through the first half of 2005, decreased from the second half of 2005 to 2010, then increased from 2011 through the first half of 2019.
- Cannabis/THC reports decreased from 2001 to 2004, slightly increased from 2005 to the first half of 2010, then decreased through the first half of 2019.
- Cocaine reports decreased from 2001 to 2004, gradually increased from 2004 to 2007, then significantly decreased through 2014. Reports of cocaine have remained relatively steady from 2014 through the first half of 2019.
- Heroin reports decreased from 2001 through 2006, then increased through 2015, followed by a steady decrease through the first half of 2019.
- Reports of acetyl fentanyl first appeared in NFLIS-Drug in 2013. Overall, they showed an S-shaped trend from 2013 to the first half of 2019. Acetyl fentanyl reports increased from 2013 through the second half of 2015, decreased through the first half of 2017, then steadily increased to the first half of 2019.
- MDMA reports decreased from 2001 to 2003, then increased through the first half of 2007. A sharp decrease in MDMA reports occurred from 2010 to 2013, followed by a gradual increase through the first half of 2019.

MDMA—3,4-methylenedioxyamphetamine

Note: Estimates are shown in half-year increments for each year from January to June 2001 through January to June 2019. Estimates are not available for acetyl fentanyl for 2001 through 2012 because acetyl fentanyl was first reported to NFLIS in 2013.
More recently, from the first half of 2018 to the first half of 2019, reports of methamphetamine (from 180,549 to 209,439 reports), acetyl fentanyl (from 2,246 to 7,307 reports), and MDMA (from 3,023 to 3,558 reports) increased significantly ($p < .05$). Reports of cannabis/THC (from 174,226 to 165,865 reports) and cocaine (from 115,425 to 108,762 reports) decreased significantly. The increase in reports of heroin (from 68,376 to 68,586 reports) was not statistically significant.

**Regional prescription drug trends**

Figures 1.5 through 1.10 show regional trends per 100,000 persons aged 15 or older for reports of fentanyl, alprazolam, oxycodone, buprenorphine, hydrocodone, and amphetamine from the first half of 2001 to the first half of 2019. These figures illustrate changes in prescription drugs reported over time, taking into account the population aged 15 years or older in each U.S. census region. Significant ($p < .05$) trend results include the following:

- For fentanyl, the West region showed a more gradual increase from 2001 to 2014 than the other regions, followed by significant increases in reports through the first half of 2019. Reports remained steady from 2001 through 2013 for the Midwest, Northeast, and South regions until significant increases began in 2014 and continued through the first half of 2019. The Midwest and Northeast regions had noticeable increases in 2006 as reflected in the national trend.

- For alprazolam, the West region showed an increasing curved trend through the first half of 2018. Similarly, the Midwest region had increases in reports that continued through the first half of 2017. The Northeast and South regions had increases from 2003 to 2010, followed by slight decreases through 2013, then continued increases through the first half of 2016. The number of reports for all four regions decreased from the first half of 2018 to the first half of 2019.

- For oxycodone, all regions except the Midwest region showed trends similar to the national trend. The Midwest region’s trend had a slower rate of decrease from 2011 through the first half of 2019, while the other regions had steeper declines in the number of reports from 2011 through the first half of 2019.

- For buprenorphine, the South region showed an S-shaped trend and, along with the Midwest region, had steady increases in reports from 2011 through the first half of 2019. Although the West and Northeast regions also had increases, they had more fluctuation in the number of reports from 2011 through the first half of 2019.

- For hydrocodone, all regions showed significant increases from 2001 through at least 2009, followed by steady decreases through the first half of 2019. Although the number of reports per 100,000 in the South region were more than twice as high as those in the Midwest region in 2010, these numbers were very similar at 3.5 and 3.4 reports per 100,000 in the first half of 2019, respectively.

- For amphetamine, the Midwest and South regions showed a steady increase in reports from the second half of 2007 through the first half of 2018 until a decrease in the first half of 2019. The Northeast region had a similar increasing trajectory that continued through the first half of 2019. The West region had a downward S-shaped trend, with larger fluctuations in the number of reports having occurred from 2001 through the first half of 2006. Unlike in the other regions, the number of reports in the West region remained steady.

More recently, from the first half of 2018 to the first half of 2019, fentanyl reports increased significantly in all regions except in the South region, and buprenorphine reports increased significantly in all regions except in the West region ($p < .05$). Amphetamine reports decreased significantly in all regions except in the Northeast region where they increased significantly. Alprazolam, oxycodone, and hydrocodone reports decreased significantly in all regions.
Figure 1.5 Regional trends in fentanyl reported per 100,000 persons aged 15 or older, January 2001–June 2019

Figure 1.6 Regional trends in alprazolam reported per 100,000 persons aged 15 or older, January 2001–June 2019

Figure 1.7 Regional trends in oxycodone reported per 100,000 persons aged 15 or older, January 2001–June 2019

Note: Estimates are shown in half-year increments for each year from January to June 2001 through January to June 2019. U.S. Census 2019 population data by age were not available for this publication. Population data for 2019 were imputed.

1 A dashed trend line indicates that estimates did not meet the criteria for precision or reliability. See Appendix A for a more detailed methodology discussion.
Figure 1.8  Regional trends in buprenorphine reported per 100,000 persons aged 15 or older, January 2001–June 2019

Figure 1.9  Regional trends in hydrocodone reported per 100,000 persons aged 15 or older, January 2001–June 2019

Figure 1.10  Regional trends in amphetamine reported per 100,000 persons aged 15 or older, January 2001–June 2019

Note: Estimates are shown in half-year increments for each year from January to June 2001 through January to June 2019. U.S. Census 2019 population data by age were not available for this publication. Population data for 2019 were imputed.

1 A dashed trend line indicates that estimates did not meet the criteria for precision or reliability. See Appendix A for a more detailed methodology discussion.
Other regional drug trends

Figures 1.11 through 1.16 present regional trends per 100,000 persons aged 15 or older for methamphetamine, cannabis/THC, cocaine, heroin, acetyl fentanyl, and MDMA reports from the first half of 2001 through the first half of 2019. Significant ($p < .05$) trends include the following:

- For methamphetamine reports, the West region had more pronounced decreases than the other regions from around 2005 through the first half of 2010. All regions showed increases beginning around 2010 and 2011 and continuing through the first half of 2019, except that the West region had a decrease in reports from the first half of 2016 to the second half of 2017, with a significant increase in the first half of 2019. By the first half of 2019, the number of reports per 100,000 persons in the Midwest region had surpassed that of the West region.

- For cannabis/THC reports, the Northeast region showed an increase from the second half of 2003 to the first half of 2008 before decreasing through the first half of 2018, while the West, South, and Midwest regions had more rolling decreasing trend lines from 2001 through the second half of 2018. By the second half of 2016 through the first half of 2019, the number of reports per 100,000 in the Midwest and South regions had decreased to numbers comparable with those for the Northeast region.

- For cocaine reports, all regions had rolling decreasing trend lines, with slight increases in reports beginning in the first half of 2017. The Midwest and Northeast regions had steady decreases in reports from the first half of 2008 through 2012. The West and South regions had steadier declines through 2016. Reports in the Northeast region continued to increase through the first half of 2019.

- For heroin reports, all regions had increasing rolling trend lines, with decreases in the number of reports beginning in the second half of 2015 for the West and Midwest regions and in the first half of 2016 for the Northeast and South regions. Reports of heroin in the West region increased from the second half of 2017 through the first half of 2019.

- Reports of acetyl fentanyl were first reported to NFLIS-Drug in the second half of 2013 in the South region, followed by reports in the other regions in the first half of 2014. For acetyl fentanyl, all regions had an initial increase in reports in the first half of 2015. Reports then significantly increased from the first half of 2017 through the first half of 2019 in the Northeast region and from the second half of 2017 through the first half of 2019 in the South and Midwest regions. The West region continued to have a much smaller number of acetyl fentanyl reports than the other regions. Reports in the West region also noticeably increased from the second half of 2017 through the second half of 2018, then decreased in the first half of 2019.

- For MDMA reports, the trend line for each region showed a decrease from 2001 through 2004, followed by an increase through the first half of 2010, although the West and Midwest regions had much steeper increases during this time. Regional MDMA trend lines decreased steadily through the second half of 2012. The number of reports in the Northeast and West regions remained steady from 2012 through the first half of 2019, while reports in the Midwest and South regions increased from the first half of 2017 through the first half of 2019.

Between the first half of 2018 and the first half of 2019, methamphetamine reports increased significantly in all regions, while MDMA reports increased significantly in all regions except in the West region ($p < .05$). Cannabis/THC reports increased significantly in the Northeast region but decreased significantly in the Midwest region. Cocaine reports increased significantly in the Northeast region but decreased significantly in the South and Midwest regions. Heroin reports increased significantly in the West region but decreased significantly in the Northeast and Midwest regions. Acetyl fentanyl reports increased significantly in all regions except in the West region where they decreased significantly.
Figure 1.11  Regional trends in methamphetamine reported per 100,000 persons aged 15 or older, January 2001–June 2019

![Graph showing regional trends in methamphetamine reported per 100,000 persons aged 15 or older, January 2001–June 2019.]

Figure 1.12  Regional trends in cannabis/THC reported per 100,000 persons aged 15 or older, January 2001–June 2019

![Graph showing regional trends in cannabis/THC reported per 100,000 persons aged 15 or older, January 2001–June 2019.]

Figure 1.13  Regional trends in cocaine reported per 100,000 persons aged 15 or older, January 2001–June 2019

![Graph showing regional trends in cocaine reported per 100,000 persons aged 15 or older, January 2001–June 2019.]

Note: Estimates are shown in half-year increments for each year from January to June 2001 through January to June 2019. U.S. Census 2019 population data by age were not available for this publication. Population data for 2019 were imputed.

1 A dashed trend line indicates that estimates did not meet the criteria for precision or reliability. See Appendix A for a more detailed methodology discussion.
**Figure 1.14** Regional trends in heroin reported per 100,000 persons aged 15 or older, January 2001–June 2019

**Figure 1.15** Regional trends in acetyl fentanyl reported per 100,000 persons aged 15 or older, January 2001–June 2019

**Figure 1.16** Regional trends in MDMA reported per 100,000 persons aged 15 or older, January 2001–June 2019

MDMA=3,4-methylenedioxymethamphetamine

Note: Estimates are shown in half-year increments for each year from January to June 2001 through January to June 2019. U.S. Census 2019 population data by age were not available for this publication. Population data for 2019 were imputed. Estimates are not available for acetyl fentanyl for 2001 through 2012 because acetyl fentanyl was first reported to NFLIS in 2013.

1 A dashed trend line indicates that estimates did not meet the criteria for precision or reliability. See Appendix A for a more detailed methodology discussion.
Section 2: Major Drug Categories

This section presents results for major drug categories. Specifically, this section presents estimates of specific drugs by drug category using the NEAR approach. All drugs mentioned in laboratories’ drug items are included in the counts. Drug categories presented in this section include narcotic analgesics, tranquilizers and depressants, anabolic steroids, phenethylamines, and synthetic cannabinoids. A total of 800,283 drug reports were submitted to State and local laboratories from January 1, 2019, through June 30, 2019, and analyzed by September 30, 2019.

Table 2.1  Narcotic Analgesics
Number and percentage of narcotic analgesic reports in the United States, January 2019–June 2019

<table>
<thead>
<tr>
<th>Narcotic Analgesics</th>
<th>Number</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fentanyl</td>
<td>47,814</td>
<td>48.13%</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>11,433</td>
<td>11.51%</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>10,245</td>
<td>10.31%</td>
</tr>
<tr>
<td>Acetyl fentanyl</td>
<td>7,307</td>
<td>7.36%</td>
</tr>
<tr>
<td>Hydrocodone</td>
<td>6,537</td>
<td>6.58%</td>
</tr>
<tr>
<td>Tramadol</td>
<td>4,645</td>
<td>4.68%</td>
</tr>
<tr>
<td>ANPP</td>
<td>2,010</td>
<td>2.02%</td>
</tr>
<tr>
<td>Morphine</td>
<td>1,529</td>
<td>1.54%</td>
</tr>
<tr>
<td>Codeine</td>
<td>1,304</td>
<td>1.31%</td>
</tr>
<tr>
<td>Valeryl fentanyl</td>
<td>1,067</td>
<td>1.07%</td>
</tr>
<tr>
<td>Methadone</td>
<td>999</td>
<td>1.01%</td>
</tr>
<tr>
<td>Carfentanil</td>
<td>951</td>
<td>0.96%</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>864</td>
<td>0.87%</td>
</tr>
<tr>
<td>Oxymorphone</td>
<td>317</td>
<td>0.32%</td>
</tr>
<tr>
<td>Fluoroisobutyryl fentanyl</td>
<td>265</td>
<td>0.27%</td>
</tr>
<tr>
<td>Other narcotic analgesics</td>
<td>2,057</td>
<td>2.07%</td>
</tr>
</tbody>
</table>

| Total Narcotic Analgesic Reports | 99,344 | 100.00% |
| Total Drug Reports              | 800,283|

ANPP=4-anilino-N-phenethyl-4-piperidine

1 Includes drug reports submitted to laboratories from January 1, 2019, through June 30, 2019, that were analyzed by September 30, 2019.
2 Numbers and percentages may not sum to totals because of rounding.

Figure 2.1  Distribution of narcotic analgesic reports within region, January 2019–June 2019

West  Midwest  Northeast  South

Number
0%
20%
40%
60%
80%
100%

Number and Percentage of Narcotic Analgesic Reports

Total Number

6,400; 28,503; 32,002; 32,439; 99,344

<table>
<thead>
<tr>
<th>Total Number</th>
<th>Fentanyl</th>
<th>Oxycodone</th>
<th>Buprenorphine</th>
<th>Acetyl fentanyl</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>6,400</td>
<td>4,452</td>
<td>4,324</td>
<td>4,132</td>
<td>1,146</td>
<td>574</td>
</tr>
<tr>
<td>28,503</td>
<td>19,623</td>
<td>13,838</td>
<td>13,382</td>
<td>3,238</td>
<td>1,854</td>
</tr>
<tr>
<td>32,002</td>
<td>25,224</td>
<td>19,110</td>
<td>18,625</td>
<td>5,058</td>
<td>2,270</td>
</tr>
<tr>
<td>32,439</td>
<td>23,933</td>
<td>17,332</td>
<td>16,952</td>
<td>4,532</td>
<td>2,462</td>
</tr>
<tr>
<td>99,344</td>
<td>67,391</td>
<td>53,556</td>
<td>52,416</td>
<td>13,872</td>
<td>5,746</td>
</tr>
</tbody>
</table>
Table 2.2

**TRANQUILIZERS AND DEPRESSANTS**

Number and percentage of tranquilizer and depressant reports in the United States, January 2019–June 2019

<table>
<thead>
<tr>
<th>Tranquilizer and Depressant Reports</th>
<th>Number</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alprazolam</td>
<td>14,586</td>
<td>49.41%</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>4,191</td>
<td>14.20%</td>
</tr>
<tr>
<td>Phencyclidine (PCP)</td>
<td>2,146</td>
<td>7.27%</td>
</tr>
<tr>
<td>Etizolam</td>
<td>1,460</td>
<td>4.94%</td>
</tr>
<tr>
<td>Diazepam</td>
<td>1,379</td>
<td>4.67%</td>
</tr>
<tr>
<td>Ketamine</td>
<td>1,331</td>
<td>4.51%</td>
</tr>
<tr>
<td>Lorazepam</td>
<td>825</td>
<td>2.79%</td>
</tr>
<tr>
<td>Flualprazolam</td>
<td>615</td>
<td>2.08%</td>
</tr>
<tr>
<td>Carisoprodol</td>
<td>556</td>
<td>1.88%</td>
</tr>
<tr>
<td>Zolpidem</td>
<td>418</td>
<td>1.42%</td>
</tr>
<tr>
<td>Cylobenzaprine</td>
<td>411</td>
<td>1.39%</td>
</tr>
<tr>
<td>Clonazolam</td>
<td>382</td>
<td>1.29%</td>
</tr>
<tr>
<td>Pregabalin</td>
<td>184</td>
<td>0.62%</td>
</tr>
<tr>
<td>Hydroxyzine</td>
<td>177</td>
<td>0.60%</td>
</tr>
<tr>
<td>Flubromazolam</td>
<td>104</td>
<td>0.35%</td>
</tr>
<tr>
<td>Other tranquilizers and depressants</td>
<td>757</td>
<td>2.56%</td>
</tr>
</tbody>
</table>

*Total Tranquilizer and Depressant Reports* 29,521 100.00%

*Total Drug Reports* 800,283

Figure 2.2 Distribution of tranquilizer and depressant reports within region, January 2019–June 2019

Table 2.3

**ANABOLIC STEROIDS**

Number and percentage of anabolic steroid reports in the United States, January 2019–June 2019

<table>
<thead>
<tr>
<th>Anabolic Steroid Reports</th>
<th>Number</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone</td>
<td>691</td>
<td>46.06%</td>
</tr>
<tr>
<td>Nandrolone</td>
<td>130</td>
<td>8.66%</td>
</tr>
<tr>
<td>Trenbolone</td>
<td>130</td>
<td>8.66%</td>
</tr>
<tr>
<td>Methandrostenolone</td>
<td>93</td>
<td>6.20%</td>
</tr>
<tr>
<td>Oxandrolone</td>
<td>79</td>
<td>5.26%</td>
</tr>
<tr>
<td>Stanozolol</td>
<td>73</td>
<td>4.85%</td>
</tr>
<tr>
<td>Boldenone</td>
<td>56</td>
<td>3.75%</td>
</tr>
<tr>
<td>Oxymetholone</td>
<td>41</td>
<td>2.73%</td>
</tr>
<tr>
<td>Drostanolone</td>
<td>36</td>
<td>2.41%</td>
</tr>
<tr>
<td>Methasterone</td>
<td>19</td>
<td>1.30%</td>
</tr>
<tr>
<td>Mesterolone</td>
<td>18</td>
<td>1.20%</td>
</tr>
<tr>
<td>Methyltestosterone</td>
<td>14</td>
<td>0.96%</td>
</tr>
<tr>
<td>Dehydrochloromethyltestosterone</td>
<td>14</td>
<td>0.93%</td>
</tr>
<tr>
<td>Fluoxymesterone</td>
<td>7</td>
<td>0.47%</td>
</tr>
<tr>
<td>Methenolone</td>
<td>4</td>
<td>0.27%</td>
</tr>
<tr>
<td>Other anabolic steroids</td>
<td>95</td>
<td>6.30%</td>
</tr>
</tbody>
</table>

*Total Anabolic Steroid Reports* 1,500 100.00%

*Total Drug Reports* 800,283

Figure 2.3 Distribution of anabolic steroid reports within region, January 2019–June 2019

---

1 Includes drug reports submitted to laboratories from January 1, 2019, through June 30, 2019, that were analyzed by September 30, 2019.

2 Numbers and percentages may not sum to totals because of rounding.
Table 2.4  
**PHENETHYLAMINES**  
Number and percentage of phenethylamine reports in the United States, January 2019–June 2019

<table>
<thead>
<tr>
<th>Phenethylamine Reports</th>
<th>Number</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methamphetamine</td>
<td>209,439</td>
<td>92.03%</td>
</tr>
<tr>
<td>Amphetamine</td>
<td>5,805</td>
<td>2.55%</td>
</tr>
<tr>
<td>MDMA</td>
<td>3,558</td>
<td>1.56%</td>
</tr>
<tr>
<td>Eutylone</td>
<td>2,800</td>
<td>1.23%</td>
</tr>
<tr>
<td>N-Ethylpentylone</td>
<td>1,393</td>
<td>0.61%</td>
</tr>
<tr>
<td>Lisdexamfetamine</td>
<td>720</td>
<td>0.32%</td>
</tr>
<tr>
<td>Benzphetamine</td>
<td>618</td>
<td>0.27%</td>
</tr>
<tr>
<td>MDA</td>
<td>479</td>
<td>0.21%</td>
</tr>
<tr>
<td>BMDP</td>
<td>390</td>
<td>0.17%</td>
</tr>
<tr>
<td>alpha-PiHP</td>
<td>289</td>
<td>0.13%</td>
</tr>
<tr>
<td>Phentermine</td>
<td>270</td>
<td>0.12%</td>
</tr>
<tr>
<td>Butyl pentyline</td>
<td>127</td>
<td>0.06%</td>
</tr>
<tr>
<td>alpha-PHP</td>
<td>119</td>
<td>0.05%</td>
</tr>
<tr>
<td>N-Butylpentylone</td>
<td>98</td>
<td>0.04%</td>
</tr>
<tr>
<td>MMMP</td>
<td>81</td>
<td>0.04%</td>
</tr>
<tr>
<td>Other phenethylamines</td>
<td>1,381</td>
<td>0.61%</td>
</tr>
<tr>
<td><strong>Total Phenethylamine Reports</strong></td>
<td><strong>227,566</strong></td>
<td><strong>100.00%</strong></td>
</tr>
<tr>
<td><strong>Total Drug Reports</strong></td>
<td><strong>800,283</strong></td>
<td></td>
</tr>
</tbody>
</table>

MDMA=3,4-methylenedioxymethamphetamine  
MDA=3,4-methylenedioxyamphetamine  
BMDP=3,4-methylenedioxy-N-benzylethylamine  
alpha-PiHP=alpha-pyrrolidinoisohexanophenone  
alpha-PHP=alpha-pyrrolidinohexanophenone  
MMMP=2-methyl-4’-(methylthio)-2-morpholinopropiophenone

1 Includes drug reports submitted to laboratories from January 1, 2019, through June 30, 2019, that were analyzed by September 30, 2019.
2 Numbers and percentages may not sum to totals because of rounding.

Figure 2.4  
Distribution of phenethylamine reports within region, January 2019–June 2019

<table>
<thead>
<tr>
<th>Region</th>
<th>Methamphetamine</th>
<th>Amphetamine</th>
<th>MDMA</th>
<th>Eutylone</th>
<th>Total Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>West</td>
<td>61,667</td>
<td>59,813</td>
<td>8,539</td>
<td>97,547</td>
<td>227,566</td>
</tr>
<tr>
<td>Midwest</td>
<td>396</td>
<td>453</td>
<td>1,559</td>
<td>1,270</td>
<td>6,061</td>
</tr>
<tr>
<td>Northeast</td>
<td>1,000</td>
<td>307</td>
<td>115</td>
<td>1,056</td>
<td>3,439</td>
</tr>
<tr>
<td>South</td>
<td>1,017</td>
<td>1,037</td>
<td>3,439</td>
<td>2,530</td>
<td>8,762</td>
</tr>
</tbody>
</table>

**Methamphetamine**
### Table 2.5

<table>
<thead>
<tr>
<th>Synthetic Cannabinoid Reports</th>
<th>Number</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>5F-MDMB-PICA</td>
<td>2,227</td>
<td>22.29%</td>
</tr>
<tr>
<td>5F-ADB</td>
<td>1,673</td>
<td>16.75%</td>
</tr>
<tr>
<td>FUB-AMB</td>
<td>911</td>
<td>9.12%</td>
</tr>
<tr>
<td>4F-MDMB-BINACA</td>
<td>887</td>
<td>8.88%</td>
</tr>
<tr>
<td>Fluoro-MDMB-PICA</td>
<td>876</td>
<td>8.77%</td>
</tr>
<tr>
<td>Fluoro-MDMB-BINACA</td>
<td>470</td>
<td>4.70%</td>
</tr>
<tr>
<td>FUB-144</td>
<td>221</td>
<td>2.21%</td>
</tr>
<tr>
<td>MMB-FUBICA</td>
<td>218</td>
<td>2.18%</td>
</tr>
<tr>
<td>MDMB-4en-PINACA</td>
<td>137</td>
<td>1.37%</td>
</tr>
<tr>
<td>Fluoro-ADB</td>
<td>108</td>
<td>1.08%</td>
</tr>
<tr>
<td>APP-BINACA</td>
<td>85</td>
<td>0.85%</td>
</tr>
<tr>
<td>ADB-FUBINACA</td>
<td>82</td>
<td>0.82%</td>
</tr>
<tr>
<td>5F-EDMB-PINACA</td>
<td>60</td>
<td>0.60%</td>
</tr>
<tr>
<td>4-CN CUMYL-BUTINACA</td>
<td>33</td>
<td>0.33%</td>
</tr>
<tr>
<td>MMB-022</td>
<td>27</td>
<td>0.27%</td>
</tr>
<tr>
<td>Other synthetic cannabinoids</td>
<td>1,976</td>
<td>19.77%</td>
</tr>
</tbody>
</table>

**Total Synthetic Cannabinoid Reports**

<table>
<thead>
<tr>
<th>Total Synthetic Cannabinoid Reports</th>
<th>9,992</th>
<th>100.00%</th>
</tr>
</thead>
</table>

**Total Drug Reports**

<table>
<thead>
<tr>
<th>Total Drug Reports</th>
<th>800,283</th>
</tr>
</thead>
</table>

1 Includes drug reports submitted to laboratories from January 1, 2019, through June 30, 2019, that were analyzed by September 30, 2019.

2 Numbers and percentages may not sum to totals because of rounding.
Overview

Since 2001, NFLIS-Drug publications have included national and regional estimates for the number of drug reports and drug cases analyzed by State and local forensic laboratories in the United States. This appendix discusses the methods used for producing these estimates, including sample selection, weighting, imputation, and trend analysis procedures. RTI International, under contract to the DEA, began implementing NFLIS-Drug in 1997. Results from a 1998 survey (updated in 2002, 2004, 2008, 2013, and 2019) provided laboratory-specific information, including annual caseloads, which was used to establish a national sampling frame of all known State and local forensic laboratories that routinely perform drug chemistry analyses. A probability proportional to size (PPS) sample was drawn on the basis of annual cases analyzed per laboratory, resulting in a NFLIS-Drug national sample of 29 laboratory systems and 31 local or municipal laboratories, and a total of 168 individual laboratories (see Appendix B for a list of participating NFLIS-Drug laboratories).

Estimates appearing in this publication are based on cases and items submitted to laboratories between January 1, 2019, and June 30, 2019, and analyzed by September 30, 2019. Analysis has shown that approximately 95% of cases submitted during an annual period are analyzed within three months of the end of the annual period (not including the approximately 30% of cases that are never analyzed).

Since 2011, the estimation procedures have accounted for multiple drugs per item. For each drug item (or exhibit) analyzed by a laboratory in the NFLIS-Drug program, up to three drugs were reported to NFLIS and counted in the estimation process. A further enhancement to account for the possibility of there being more than three drugs per item was introduced in 2017 for the 2016 Annual Report. All drugs reported in an item are now counted in the estimation process. This change ensures that the estimates will take into consideration all reported substances, including emerging drugs of interest that may typically be reported as the fourth or fifth drug within an item. This change was implemented in the 2016 data processing cycle and for future years. Although this change could not be applied to reporting periods before 2016, the 2016 data showed that 99.97% of drug reports are captured in the first, second, or third drug report for any item; therefore, no statistical adjustments were deemed necessary to maintain the trend with prior years.

Currently, laboratories representing more than 98% of the national drug caseload participate in NFLIS-Drug, with about 97% of the national caseload reported for the current reporting period. Because of the continued high level of reporting among laboratories, the NEAR (National Estimates Based on All Reports) method, which has strong statistical advantages for producing national and regional estimates, continues to be implemented.

NEAR Methodology

In NFLIS-Drug publications before 2011, data reported by nonsampled laboratories were not used in national or regional estimates. However, as the number of nonsampled laboratories reporting to NFLIS-Drug increased, it began to make sense to consider ways to use the data they submitted. Under NEAR, the “volunteer” laboratories (i.e., the reporting nonsampled laboratories) represent themselves and are no longer represented by the reporting sampled laboratories. The volunteer laboratories are assigned weights of one; hence, the weights of the sampled and responding laboratories are appropriately adjusted downward. The outcome is that the estimates are more precise, especially for recent years, which include a large number of volunteer laboratories. More precision allows for more power to detect trends and fewer suppressed estimates in Tables 1.1 and 1.2 of the NFLIS-Drug Annual and Midyear Reports.

NEAR imputations and adjusting for missing monthly data in reporting laboratories

Because of technical and other reporting issues, some laboratories do not report data for every month during a given reporting period, resulting in missing monthly data. If a laboratory reports fewer than six months of data for the annual estimates (fewer than three months for the semiannual estimates), it is considered nonreporting, and its reported data are not included in the estimates. Otherwise, imputations are performed separately by drug for laboratories that are missing monthly data, using drug-specific proportions generated from laboratories that are reporting all months of data. This imputation method is used for cases, items, and drug-specific reports and accounts for the typical month-to-month variation and the size of the laboratory requiring imputation. The general idea is to use the nonmissing months to assess the size of the laboratory requiring imputation and then to apply the seasonal pattern exhibited by all laboratories with no missing data. Imputations of monthly case counts are created using the following ratio ($r_L$):

$$r_L = \frac{\sum_{m \in R_L} c_{L,m}}{\sum_{m} c_{m}}$$

where

- $R_L$ = set of all nonmissing months in laboratory $L$,
- $c_{L,m}$ = case count for laboratory $L$ in month $m$, and
- $c_{m}$ = mean case counts for all laboratories reporting complete data.

1. The case and item loads for the nonsampled laboratories were used in calculating the weights.

2. In the current reporting period, for example, out of 113 nonsampled laboratories and laboratory systems, 86 (or 76%) reported.
Monthly item counts are imputed for each laboratory using an estimated item-to-case ratio \( s_{L} \) for nonmissing monthly item counts within the laboratory. The imputed value for the missing monthly number of items in each laboratory is calculated by multiplying \( c_{L,m} \) by \( s_{L} \):

\[
s_{L} = \frac{\sum_{m \in R_{L}} i_{L,m}}{\sum_{m \in R_{L}} c_{L,m}},
\]

where

\[
R_{L} = \text{set of all nonmissing months in laboratory } L, \\
i_{L,m} = \text{item count for laboratory } L \text{ in month } m, \text{ and} \\
c_{L,m} = \text{case count for laboratory } L \text{ in month } m.
\]

Drug-specific case and report counts are imputed using the same imputation techniques presented previously for the case and item counts. The total drug, item, and case counts are calculated by aggregating the laboratory and laboratory system counts for those with complete reporting and those that require imputation.

**NEAR imputations and drug report-level adjustments**

Most forensic laboratories classify and report case-level analyses consistently in terms of the number of packages of a particular pill. A small number, however, do not produce drug report-level counts in the same way as those submitted by the vast majority. Instead, they report as items the count of the individual pills themselves. Laboratories that consider items in this manner also consider drug report-level counts in this same manner. Drug report-to-case ratios for each drug are produced for the similarly sized laboratories, and these drug-specific ratios are then used to adjust the drug report counts for the relevant laboratories.

**NEAR weighting procedures**

Each NFLIS-Drug reporting laboratory is assigned a weight to be used in calculating design-consistent, nonresponse-adjusted estimates. Two weights are created: one for estimating cases and one for estimating drug reports. The weight used for case estimation is based on the caseload for every laboratory in the NFLIS-Drug population, and the weight used for drug reports’ estimation is based on the item load for every laboratory in the NFLIS-Drug population. For reporting laboratories, the caseload and item load used in weighting are the reported totals. For nonreporting laboratories, the caseload and item load used in weighting are based on completion-based data obtained from an updated laboratory survey administered in 2019, or, in some cases, via direct communication with laboratories or other external sources.

When the NFLIS-Drug sample was originally drawn, State systems (and the multilaboratory local systems known to exist) were treated as a single laboratory; so, if a State system was selected, all laboratories in the system were selected. The sampling frame of laboratories was divided into four strata by two stratifiers: (1) type of laboratory (State system or municipal or county laboratory) and (2) determination of “certainty” laboratory status. The criteria used in selecting the certainty laboratories included (1) size, (2) region, (3) geographical location, and (4) other special considerations (e.g., strategic importance of the laboratory). To ensure that the NFLIS-Drug sample had strong regional representation, U.S. census regions were used as the geographical divisions to guide the selection of certainty laboratories and systems. Some large laboratories were automatically part of the original NFLIS-Drug sample because they were deemed critically important to the calculation of reliable estimates.

Each weight has two components, the design weight and the nonresponse adjustment factor, the product of which is the final weight used in estimation. After imputation, the final item weight is based on the item count, and the final case weight is based on the case count of each laboratory or laboratory system. The final weights are used to calculate national and regional estimates. The first component, the design weight, is based on the proportion of the caseload and item load of the NFLIS-Drug universe represented by the individual laboratory or laboratory system. This step takes advantage of the original PPS sample design and provides precise estimates as long as the drug-specific case and report counts are correlated with the overall caseload and item load.

During the weighting process, laboratories are further categorized into 16 strata by region (Northeast, Midwest, South, and West), in addition to type of laboratory (State system or municipal or county laboratory) and certainty status, which were both used in defining the sampling strata. For noncertainty reporting laboratories in the sample (and reporting laboratories in the certainty strata with nonreporting laboratories), the design-based weight for each laboratory is calculated as follows:

\[
\text{Design Weight}_{i} = A(B \times \text{Case [item] Count for Laboratory or Laboratory System } i),
\]

where

\[
i = \text{ith laboratory or laboratory system;}
\]

\[
A = \text{sum of the case (item) counts for all of the laboratories and laboratory systems (sampled and nonsampled) within a specific stratum, excluding certainty strata and the volunteer stratum; and}
\]

\[
B = \text{number of sampled laboratories and laboratory systems within the same stratum, excluding certainty strata and the volunteer stratum.}
\]
Certainty laboratories are assigned a design weight of one.\textsuperscript{2}

The second component, the nonresponse adjustment factor, adjusts the weights of the reporting and sampled laboratories to account for the nonreporting and sampled laboratories. The nonresponse (NR) adjustment, for certainty and noncertainty laboratories, is calculated as follows:

\[ NR_i = \frac{C}{D} \]

where

- \( f = \) stratum;
- \( C = \) number of sampled laboratories and laboratory systems in the stratum, excluding the volunteer stratum; and
- \( D = \) number of laboratories and laboratory systems in the stratum that are sampled and reporting.

Because volunteer laboratories represent only themselves, they are automatically assigned a final weight of one.

**NEAR estimation**

The estimates in this publication are the weighted sum of the counts from each laboratory. The weighting procedures make the estimates more precise by assigning large weights to small laboratories and small weights to large laboratories.\textsuperscript{21} Because most of the values being estimated tend to be related to laboratory size, the product of the weight and the value to be estimated tend to be relatively stable across laboratories, resulting in precise estimates.

A finite population correction is also applied to account for the high sampling rate. In a sample-based design, the sampling fraction, which is used to create the weights, equals the number of sampled laboratories divided by the number of laboratories in the NFLIS-Drug universe. Under NEAR, the sampling fraction equals the number of sampled laboratories divided by the sum of the number of sampled laboratories and the number of nonreporting, nonsampled laboratories. Volunteer laboratories are not included in the sampling fraction calculation. Thus, the NEAR approach makes the sampling rate even higher because volunteer laboratories do not count as nonsampled laboratories.

**Suppression of Unreliable Estimates**

For some drugs, such as cannabis/THC and cocaine, thousands of reports occur annually, allowing for reliable national prevalence estimates to be computed. For other drugs, reliable and precise estimates cannot be computed because of a combination of low report counts and substantial variability in report counts between laboratories. Thus, a suppression rule was established. Precision and reliability of estimates are evaluated using the relative standard error (RSE), which is the ratio between the standard error of an estimate and the estimate. Drug estimates with an RSE > 50% are suppressed and not shown in the tables.

**Statistical Techniques for Trend Analysis**

Two types of analyses to compare estimates across years are used. The first is called prior-year comparisons and compares national and regional estimates from January 2018 through June 2018 with those from January 2019 through June 2019. The second is called long-term trends and examines trends in the semiannual national and regional estimates from January 2001 through June 2019. The long-term trends method described below was implemented beginning with the 2012 Midyear Report. This method offers the ability to identify linear and curved trends, unlike the method used in previous NFLIS-Drug publications. Both types of trend analyses are described below. For the region-level prior-year comparisons and long-term trends, the estimated drug reports are standardized to the most recent regional population totals for persons aged 15 years or older.

**Prior-year comparisons**

For selected drugs, the prior-year comparisons statistically compare estimates in Table 1.1 of this publication with estimates in Table 1.1 of the 2018 Midyear Report. The specific test examines whether the difference between any two estimates is significantly different from zero. A standard \( t \) test is completed using the statistic,

\[
t_{df} = \frac{\hat{T}_{2019} - \hat{T}_{2018}}{\sqrt{\text{var}(\hat{T}_{2019}) + \text{var}(\hat{T}_{2018}) - 2ab \text{cov}(\hat{T}_{2018}, \hat{T}_{2019})}},
\]

where

- \( df = \) appropriate degrees of freedom (number of laboratories minus number of strata);
- \( \hat{T}_{2019} = \) estimated total number of reports for the given drug for January 2019 through June 2019;
- \( \hat{T}_{2018} = \) estimated total number of reports for the given drug for January 2018 through June 2018;
- \( \text{var}(\hat{T}_{2019}) = \) variance of \( \hat{T}_{2019} \);
- \( \text{var}(\hat{T}_{2018}) = \) variance of \( \hat{T}_{2018} \); and
- \( \text{cov}(\hat{T}_{2018}, \hat{T}_{2019}) = \) covariance between \( \hat{T}_{2018} \) and \( \hat{T}_{2019} \).

For the national prior-year comparisons, \( a = b = 1 \). For the regional prior-year comparisons, \( a = 100,000 \) divided by the regional population total for 2019, and \( b = 100,000 \) divided by the regional population total for 2018.

The percentile of the test statistic in the \( t \) distribution determines whether the prior-year comparison is statistically significant (a two-tailed test at \( \alpha = .05 \)).
Long-term trends

A long-term trend analysis is performed on the January 2001 through June 2019 semiannual national estimates of totals and regional estimates of rates for selected drug reports. Acetyl fentanyl was introduced in the 2019 Midyear Report as one of the selected drugs of interest. First reports of acetyl fentanyl in NFLIS occurred in 2013; therefore, the long-term trend analysis for this drug is restricted to January 2013 through June 2019. The models allow for randomness in the totals and rates due to the sample and the population. That is, for the vector of time period totals over that time,

\[ \mathbf{Y}^T \equiv (Y_1, Y_2, \ldots, Y_{37}) , \]

and for the estimates,

\[ \hat{\mathbf{Y}}^T \equiv (\hat{Y}_1, \hat{Y}_2, \ldots, \hat{Y}_{37}) , \]

the regression model is

\[ \hat{\mathbf{Y}} = \mathbf{X}\beta + \eta + \epsilon , \]

where

\[ \eta = \hat{\mathbf{Y}} - \mathbf{Y} \]

is a \( 37 \times 1 \) vector of errors due to the probability sample, and

\[ \epsilon = 37 \times 1 \] vector of errors due to the underlying model.

Randomness due to the sample exists because only a sample of all eligible laboratories has been randomly selected to be included. Randomness due to the population exists because many factors that can be viewed as random contribute to the specific total reported by a laboratory in a time period. For example, not all drug seizures that could have been made were actually made, and there may have been some reporting errors. If rates (per 100,000 persons aged 15 years or older) and not totals are of interest, the above model can be applied to \( \hat{\mathbf{Y}}' = \hat{\mathbf{Y}}/c \), where \( c \) equals 100,000 divided by the 15-or-older regional population size as given by the U.S. Census Bureau.

The regression model used to perform the analysis is

\[ Y_t = \alpha_0 + \alpha_1 t + \alpha_2 t^2 + \cdots + \alpha_m t^m + \epsilon_t \quad t = 1, \ldots, T , \]

where

\[ Y_t = \text{the population total value, considered to be a realization of the underlying model; and} \]

\[ \epsilon_t = \text{one of a set of 37 independent normal variates with a mean of zero and a variance of } \sigma^2 . \]

The model allows for a variety of trend types, depending on the maximal polynomial degree of the analysis, such as the following: linear (straight line; \( m = 1 \)), quadratic (U-shaped; \( m = 2 \)), cubic (S-shaped; \( m = 3 \)), quartic (higher-order shape; \( m = 4 \)), and quintic (higher-order shape; \( m = 5 \)). Because it is a model for \( Y_t \) but the sample estimates \( \hat{Y}_t \) differ by the sampling error, estimation was performed by restricted maximum likelihood (REML), allowing for the two sources of error.

To implement the regression model, point estimates of totals \( \hat{Y}_t \) and their standard errors are obtained for all 37 semiannual periods beginning with the January to June 2001 period and ending with the January to June 2019 period. Sampling standard errors are estimated as the full sampling variance-covariance matrix \( S \) over these 37 periods. The \( S \) matrix contains variances in totals at any period and covariances in totals between any two periods, thus giving a very general modeling of the sampling variance structure. The variance-covariance matrix of the totals is then \( \mathbf{V}[\hat{\mathbf{Y}}] = \sigma^2 \mathbf{I} + \mathbf{S} \), where \( \mathbf{I} \) is the identity matrix.

Before the 2016 Annual Report, the variance and covariance components of the \( \mathbf{S} \) matrix for the means were estimated simultaneously. The variance-covariance matrix for the means was then converted into a variance-covariance matrix for the totals. A change was introduced in 2017 in which the covariances of the totals are directly estimated, and the estimation of the covariance of the means is no longer necessary. This change in the computation of the covariance of totals provides an incremental improvement over the old approach and theoretically provides more valid statistical inferences. In addition, it creates consistency in the covariance estimation between these long-term trends and the prior-year comparisons.

Regression coefficients are estimated using the REML method. Because higher-order polynomial regression models generally show strong collinearity among predictor variables, the model is reparameterized using orthogonal polynomials. The reparameterized model is

\[ Y_t = \beta_0 X_0(t) + \beta_1 X_1(t) + \beta_2 X_2(t) + \cdots + \beta_m X_m(t) + \epsilon_t \quad t = 1, \ldots, T , \]

where

\[ X_0(t) = 1/\sqrt{T} \]

for all \( t \), and

\[ X_1(t), \ldots, X_m(t) \]

provide contributions for the first-order (linear), second-order (quadratic), and higher-order polynomials.

Note that the error term is the same in the original model and the reparameterized model because the fitted surface is the same for both models. The model is further constrained to have regression residuals sum to zero, a constraint that is not guaranteed by theory for these models but is considered to improve model fit because of an approximation required to estimate \( \mathbf{S} \). Standard errors of the regression trend estimates are obtained by simulation.

Final models are selected after testing for the significance of coefficients at the \( \alpha = 0.05 \) level (\( \rho < .05 \)), which means that if the trend of interest (linear, quadratic, or other higher-order polynomial) was in fact zero, then there would be a 5% chance that the trend would be detected as statistically significant when in fact it is not. Final fitted models are most easily interpreted using graphical plots.
### Appendix B: NFLIS-Drug Participating and Reporting Forensic Laboratories

#### State | Lab Type | Laboratory Name | Reporting
---|---|---|---
AK | State | Alaska Department of Public Safety | ✓
AL | State | Alabama Department of Forensic Sciences (5 sites) | ✓
AR | State | Arkansas State Crime Laboratory (2 sites) | ✓
AZ | State | Arizona Department of Public Safety, Scientific Analysis Bureau (4 sites) | ✓
CA | State | California Department of Justice (10 sites) | ✓
| Local | Alameda County Sheriff's Office Crime Laboratory (San Leandro) | ✓
| Local | Contra Costa County Sheriff's Office (Martinez) | ✓
| Local | Fresno County Sheriff's Forensic Laboratory | ✓
| Local | Kern County District Attorney's Office (Bakersfield) | ✓
| Local | Long Beach Police Department | ✓
| Local | Los Angeles County Sheriff's Department (4 sites) | ✓
| Local | Los Angeles Police Department | ✓
| Local | Oakland Police Department Crime Laboratory | ✓
| Local | Orange County Sheriff's Department (Santa Ana) | ✓
| Local | Sacramento County District Attorney's Office | ✓
| Local | San Bernardino County Sheriff's Department | ✓
| Local | San Diego County Criminalistics Laboratory | ✓
| Local | San Diego Police Department | ✓
| Local | San Francisco Police Department | ✓
| Local | San Mateo County Sheriff's Office (San Mateo) | ✓
| Local | Santa Clara County District Attorney's Office (San Jose) | ✓
| Local | Solano County District Attorney Bureau of Forensic Services | ✓
| Local | Ventura County Sheriff's Department | ✓
CO | State | Colorado Bureau of Investigation (4 sites) | ✓
| Local | Colorado Springs Police Department | ✓
| Local | Denver Police Department Crime Laboratory | ✓
| Local | Unified Metropolitan Forensic Laboratory (Aurora) | ✓
CT | State | Connecticut Department of Public Safety | ✓
DE | State | Chief Medical Examiner's Office | ✓
FL | State | Florida Department of Law Enforcement (5 sites) | ✓
| Local | Broward County Sheriff's Office (Fort Lauderdale) | ✓
| Local | Indian River Crime Laboratory (Fort Pierce) | ✓
| Local | Manatee County Sheriff's Office (Bradenton) | ✓
| Local | Miami-Dade Police Department Crime Laboratory | ✓
| Local | Palm Beach County Sheriff's Office Crime Laboratory (West Palm Beach) | ✓
| Local | Pinellas County Forensic Laboratory (Largo) | ✓
| Local | Sarasota County Sheriff's Office | ✓
GA | State | Georgia State Bureau of Investigation (6 sites) | ✓
| Local | Honolulu Police Department | ✓
IA | State | Iowa Division of Criminal Investigations | ✓
ID | State | Idaho State Police (3 sites) | ✓
IL | State | Illinois State Police (6 sites) | ✓
| Local | DuPage County Forensic Science Center (Wheaton) | ✓
| Local | Northern Illinois Police Crime Laboratory (Chicago) | ✓
IN | State | Indiana State Police Laboratory (4 sites) | ✓
| Local | Indianapolis-Marion County Forensic Laboratory (Indianapolis) | ✓
KS | State | Kansas Bureau of Investigation (3 sites) | ✓
| Local | Johnson County Sheriff's Office (Mission) | ✓
| Local | Sedgwick County Regional Forensic Science Center (Wichita) | ✓
KY | State | Kentucky State Police (6 sites) | ✓
LA | State | Louisiana State Police | ✓
| Local | Acadia Criminalistics Laboratory (New Iberia) | ✓
| Local | Jefferson Parish Sheriff's Office (Metairie) | ✓
| Local | New Orleans Police Department Crime Laboratory | ✓
| Local | North Louisiana Criminalistics Laboratory System (3 sites) | ✓
| Local | Southwest Louisiana Criminalistics Laboratory (Lake Charles) | ✓
| Local | St. Tammany Parish Sheriff's Office Crime Laboratory (Slidell) | ✓
MA | State | Massachusetts State Police | ✓
| Local | University of Massachusetts Medical School (Worcester) | ✓
MD | State | Maryland State Police Forensic Services Division (3 sites) | ✓
| Local | Anne Arundel County Police Department (Millersville) | ✓
| Local | Baltimore City Police Department | ✓
| Local | Baltimore County Police Department (Towson) | ✓
| Local | Montgomery County Police Department Crime Laboratory (Rockville) | ✓
| Local | Prince George's County Police Department (Landover) | ✓
ME | State | Maine Department of Health and Human Services | ✓
MI | State | Michigan State Police (8 sites) | ✓
| Local | Oakland County Sheriff's Office Forensic Science Laboratory (Pontiac) | ✓
MN | State | Minnesota Bureau of Criminal Apprehension (2 sites) | ✓
| Local | Kenosha County Division of Health Services | ✓
MO | State | Missouri State Highway Patrol (9 sites) | ✓
| Local | KCMD Regional Crime Laboratory (Kansas City) | ✓
| Local | St. Charles County Police Department Criminalistics Laboratory (O'Fallon) | ✓
| Local | St. Louis County Police Department Crime Laboratory (Clayton) | ✓
| Local | St. Louis Police Department | ✓
MS | State | Mississippi Department of Public Safety (4 sites) | ✓
| Local | Jackson Police Department Crime Laboratory | ✓
| Local | Tupelo Police Department | ✓
MT | State | Montana Forensic Science Division | ✓
NC | State | North Carolina State Bureau of Investigation (3 sites) | ✓
| Local | Charlotte-Mecklenburg Police Department | ✓
| Local | Raleigh/Wake City-County Bureau of Identification | ✓
ND | State | North Dakota Crime Laboratory Division | ✓
NE | State | Nebraska State Patrol Criminalistics Laboratory | ✓
NH | State | New Hampshire State Police Forensic Laboratory | ✓
NJ | State | New Jersey State Police (4 sites) | ✓
| Local | Burlington County Sheriff's Office (Mt. Holly) | ✓
| Local | Cape May County Prosecutor's Office | ✓
| Local | Hudson County Prosecutor's Office (Jersey City) | ✓
| Local | Ocean County Sheriff's Department (Toms River) | ✓
| Local | Union County Prosecutor's Office (Westfield) | ✓
NM | State | New Mexico Department of Public Safety (3 sites) | ✓
| Local | Albuquerque Police Department | ✓
NV | Local | Henderson City Crime Laboratory | ✓
| Local | Las Vegas Metropolitan Police Crime Laboratory | ✓
| Local | Washoe County Sheriff's Office Crime Laboratory (Reno) | ✓
NY | State | New York State Police (4 sites) | ✓
| Local | Erie County Central Police Services Laboratory (Buffalo) | ✓
| Local | Nassau County Office of Medical Examiner (East Meadow) | ✓
| Local | New York City Police Department Crime Laboratory | ✓
| Local | Niagara County Sheriff's Office Forensic Laboratory (Lockport) | ✓
| Local | Onondaga County Center for Forensic Sciences (Syracuse) | ✓
| Local | Suffolk County Crime Laboratory (Hauppauge) | ✓
| Local | Westchester County Forensic Sciences Laboratory (Valhalla) | ✓
| Local | York County Police Department Forensic Science Laboratory | ✓
OH | State | Ohio Bureau of Criminal Identification & Investigation (4 sites) | ✓
| Local | Ohio State Highway Patrol | ✓
| Local | Canton-Stark County Crime Laboratory (Canton) | ✓
| Local | Columbus Police Department | ✓
| Local | Cuyahoga County Regional Forensic Science Laboratory (Cleveland) | ✓
| Local | Hamilton County Coroner's Office (Cincinnati) | ✓
| Local | Lake County Regional Forensic Laboratory (Painesville) | ✓
| Local | Lorain County Crime Laboratory (Elyria) | ✓
| Local | Mansfield Police Department | ✓
| Local | Miami Valley Regional Crime Laboratory (Dayton) | ✓
| Local | Newark Police Department Forensic Services | ✓
| Local | Toledo Police Forensic Laboratory | ✓
OK | State | Oklahoma State Bureau of Investigation (4 sites) | ✓
| Local | Tulsa Police Department Forensic Laboratory | ✓
OR | State | Oregon State Police Forensic Services Division (5 sites) | ✓
| Local | Virginia State Police Crime Laboratory | ✓
| Local | Allegheny Office of the Medical Examiner Forensic Laboratory (Pittsburgh) | ✓
| Local | Philadelphia Police Department Forensic Science Laboratory | ✓
PA | State | Pennsylvania State Police Crime Laboratory | ✓
| Local | Allegheny Office of the Medical Examiner Forensic Laboratory (Pittsburgh) | ✓
| Local | Philadelphia Police Department Forensic Science Laboratory | ✓
RI | State | Rhode Island Office of the Medical Examiner | ✓
| Local | Providence Police Department Crime Laboratory | ✓
| Local | Rhode Island Forensic Laboratory | ✓
| Local | Newport Police Department Crime Laboratory | ✓
SC | State | South Carolina Law Enforcement Division | ✓
| Local | Anderson/Oconee Regional Forensics Laboratory | ✓
| Local | Charleston Police Department | ✓
| Local | Richland County Sheriff's Department Forensic Sciences Laboratory (Columbia) | ✓
| Local | Spartanburg Police Department | ✓
SD | State | South Dakota Department of Public Health Laboratory | ✓
| Local | Rapid City Police Department | ✓
TN | State | Tennessee Bureau of Investigation (3 sites) | ✓
TX | State | Texas Department of Public Safety (13 sites) | ✓
| Local | Austin Police Department | ✓
| Local | Bexar County Criminal Investigations Laboratory (San Antonio) | ✓
| Local | Brazoria County Sheriff's Office Crime Laboratory (Angleton) | ✓
| Local | Dallas Institute of Forensic Sciences | ✓
| Local | Fort Worth Police Department Criminalistics Laboratory | ✓
| Local | Harris County Institute of Forensic Sciences Crime Laboratory (Houston) | ✓
| Local | Houston Forensic Science Center | ✓
| Local | Jefferson County Sheriff's Regional Crime Laboratory (Beaumont) | ✓
UT | State | Utah Department of Public Safety (3 sites) | ✓
VA | State | Virginia Department of Forensic Science (4 sites) | ✓
| Local | Virginia State Police | ✓
| Local | Vermont State Police | ✓
WA | State | Washington State Patrol (6 sites) | ✓
| Local | Kenosha County Division of Health Services | ✓
WI | State | Wisconsin Department of Justice (3 sites) | ✓
| Local | Kenosha County Division of Health Services | ✓
WV | State | West Virginia State Police | ✓
| Local | West Virginia Crime Laboratory | ✓
WY | State | Wyoming State Forensic Laboratory | ✓
| Local | Institute of Forensic Science of Puerto Rico Criminalistics Laboratory (3 sites) | ✓
**This list identifies laboratories that are participating in and reporting to NFLIS-Drug as of January 31, 2020.**
**This laboratory is not currently conducting drug chemistry analyses. Cases for the agencies it serves are being analyzed via contracts or agreements with other laboratories.**
**The New York City Police Department Crime Laboratory currently reports summary data.**


**Benefits**

The systematic collection and analysis of drug identification data aid our understanding of the Nation’s illicit drug problem. NFLIS-Drug serves as a resource for supporting drug scheduling policy and drug enforcement initiatives nationally and in specific communities around the country.

Specifically, NFLIS-Drug helps the drug control community achieve its mission by

- providing detailed information on the prevalence and types of controlled substances secured in law enforcement operations;
- identifying variations in controlled and noncontrolled substances at the national, State, and local levels;
- identifying emerging drug problems and changes in drug availability in a timely fashion;
- monitoring the diversion of legitimately marketed drugs into illicit channels;
- providing information on the characteristics of drugs, including quantity, purity, and drug combinations; and
- supplementing information from other drug sources, including the National Survey on Drug Use and Health (NSDUH) and the Monitoring the Future (MTF) study.

NFLIS-Drug is an opportunity for State and local laboratories to participate in a useful, high-visibility initiative. Participating laboratories regularly receive reports that summarize national and regional data. In addition, the Data Query System (DQS) is a secure website that allows NFLIS-Drug participants—including State and local laboratories, the DEA, and other Federal drug control agencies—to run customized queries on the NFLIS-Drug data.

**Limitations**

NFLIS-Drug has limitations that must be considered when interpreting findings generated from the database.

- Currently, NFLIS-Drug includes data from Federal, State, and local forensic laboratories. Federal data are shown separately in this publication. Efforts are under way to enroll additional Federal laboratories.
- NFLIS-Drug includes drug chemistry results from completed analyses only. Drug evidence secured by law enforcement but not analyzed by laboratories is not included in the database.
- National and regional estimates may be subject to variation associated with sample estimates, including nonresponse bias.
- State and local policies related to the enforcement and prosecution of specific drugs may affect drug evidence submissions to laboratories for analysis.
- Laboratory policies and procedures for handling drug evidence vary. Some laboratories analyze all evidence submitted to them, whereas others analyze only selected case items. Many laboratories do not analyze drug evidence if the criminal case was dismissed from court or if no defendant could be linked to the case.
- Laboratories vary with respect to the records they maintain. For example, some laboratories’ automated records include the weight of the sample selected for analysis (e.g., the weight of one of five bags of powder), whereas others record total weight.
PUBLIC DOMAIN NOTICE

All material appearing in this publication is in the public domain and may be reproduced or copied without permission from the U.S. Drug Enforcement Administration. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization of the U.S. Drug Enforcement Administration, U.S. Department of Justice. Citation of the source is appreciated.

Suggested citation:

OBTAINING COPIES OF THIS PUBLICATION

Electronic copies of this publication can be downloaded from the NFLIS website at https://www.nflis.deadiversion.usdoj.gov.